Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab versus placebo in systemic sclerosis
NL-OMON43973Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic sclerosis (SSc) comparing Tocilizumab weekly with Placebo weekly (2 arms). Primary endpoint: Change in modified Rodnan Skin Score. Started May 2016; status: active, not recruiting.
02
Drugs
tocilizumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NL-OMON43973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43973.